ResoTher Pharma develops peptide-based drugs that utilize resolution therapy to target neutrophil-driven inflammation in cardiovascular diseases. The company aims to improve patient outcomes by providing effective treatment options for conditions where inflammation is a key pathological factor.
Funding
$3.8M raised to dateRaised to date based on public sources. This may differ from the amount the company actually raised and is based only on what is publicly available on the internet.
Founders
Product
Problem
Cardiovascular diseases often involve excessive neutrophil-driven inflammation, which contributes to tissue damage and impaired patient outcomes. Current treatments may not adequately address this inflammatory component, leaving a need for therapies that actively promote resolution of inflammation.
Solution
ResoTher Pharma is developing peptide-based drugs that act as resolution therapy, specifically targeting neutrophil-driven inflammation in cardiovascular diseases. Their approach aims to promote the natural resolution of inflammation, leading to improved healing and reduced long-term damage. By modulating the inflammatory response at a molecular level, ResoTher Pharma's therapeutics offer a targeted strategy to address the underlying pathology of cardiovascular conditions. These novel medicines are designed to provide effective treatment options for patients where inflammation is a key factor in disease progression. The company is currently in clinical stage development, evaluating the efficacy and safety of their lead candidate in relevant patient populations.
Target Audience
The primary target audience includes patients suffering from cardiovascular diseases with a significant inflammatory component, as well as healthcare providers specializing in cardiology and related fields.
Features
- Peptide-based therapeutics designed for resolution therapy
- Targets neutrophil-driven inflammation in cardiovascular diseases
- Promotes the natural resolution of inflammation
- Aims to improve healing and reduce long-term tissue damage
- Clinical-stage development with ongoing Phase 2a clinical trial in myocardial infarction patients